The TRITON versus PLATO trials: differences beyond platelet inhibition

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Clopidogrel has been the standard oral antiplatelet agent for preventing thrombotic events.
• Recent trials have introduced new agents, challenging clopidogrel's established role.
• Acute coronary syndrome (ACS) management requires effective antiplatelet therapy.

Purpose of the Study:

• To compare the efficacy and safety of ticagrelor and prasugrel versus clopidogrel in ACS patients.
• To evaluate long-term outcomes, including mortality, myocardial infarction, and bleeding events.
• To assess the potential of ticagrelor and prasugrel to change the current antiplatelet therapy landscape.

Main Methods:

• Indirect comparison of data from the TRITON and PLATO clinical trials.
• Analysis of patient populations with acute coronary syndrome (ACS).
• Evaluation of secondary endpoints such as myocardial infarction (MI) and bleeding complications.

Main Results:

• Ticagrelor showed superiority to prasugrel in ACS patients, with significant reductions in mortality and myocardial infarction.
• Ticagrelor demonstrated a growing long-term vascular benefit and fewer fatal bleeding events compared to prasugrel.
• Prasugrel implementation may be limited by trial design, bleeding risks, and potential mortality increase in certain ACS subgroups.

Conclusions:

• Ticagrelor is poised to significantly alter oral antiplatelet therapy, particularly for high-risk ACS patients, diabetics, and those with recurrent events.
• Prasugrel's broad implementation faces challenges due to safety concerns and less convincing efficacy data compared to ticagrelor.
• While ticagrelor offers advantages, clopidogrel's use may persist due to economic factors and discontinuation rates.